Subchronic MK-801 behavioural deficits in rats: Partial reversal by the novel nitrate GT 1061

Pharmacology Biochemistry and Behavior

Volumn 91, Issue 4, 2009, Pages 495-502

  Beninger, Richard J ^a   Forsyth, Jennifer K ^a   Van Adel, Michael ^a   Reynolds, James N ^a   Boegman, Roland J ^a   Jhamandas, Khem ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Chlormethiazole; GABA; Locomotor activity; Nitric oxide; Schizophrenia; Water maze

Indexed keywords

4 AMINOBUTYRIC ACID; 4 METHYL 5 (2 NITROXYETHYL)THIAZOLE; AMPHETAMINE; CLOMETHIAZOLE; DIZOCILPINE; GT 1061; NITRIC ACID DERIVATIVE; NITRIC OXIDE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HABITUATION; LEARNING; LOCOMOTION; MALE; MAZE TEST; MOTOR ACTIVITY; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

AMPHETAMINE; ANIMALS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; CHLORMETHIAZOLE; COGNITION DISORDERS; DATA INTERPRETATION, STATISTICAL; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; HYPNOTICS AND SEDATIVES; MALE; MAZE LEARNING; MOTOR ACTIVITY; NITRATES; RATS; RATS, SPRAGUE-DAWLEY; REVERSAL LEARNING;

RATTUS;

EID: 58349090210     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2008.09.003     Document Type: Article

References (80)

1. Abdul-Monim Z., Neill J.C., and Reynolds G.P. Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. J Psychopharmacol 21 (2007) 198-205
2. Abdul-Monim Z., Reynolds G.P., and Neill J.C. The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in reversal learning task in the rat. J Psychopharmacol 17 (2003) 57-66
3. Adams J.P., and Sweatt J.D. Molecular psychology: roles for the ERK MAP kinase cascade in memory. Annu Rev Pharmacol Toxicol 42 (2002) 135-163
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR. Fourth Edition (2000), American Psychiatric Publishing Inc, Jaypee
5. Anderson J.A., and Pouzet B. Spatial memory deficits induced by perinatal treatment of rats with PCP and reversal effect of D-serine. Neuropsychopharmacol 29 (2004) 1080-1090
6. Andoh T., Chiueh C., and Chock P. Cyclic GMP-dependent protein kinase regulates the expression of thioredoxin and thioredoxin peroxidase-1 during hormesis in response to oxidative stress-induced apoptosis. J Biol Chem 278 (2003) 885-890
7. Balla A., Koneru R., Smiley J., Sershen H., and Javitt D. Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release. Neuropsychopharmacol 25 (2001) 157-164
8. Beasley C.L., and Reynolds G.P. Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr Res 24 (1997) 349-355
9. Benes F.M., Kwok E.W., Vincent S.L., and Todtenkopf M.S. A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives. Biol Psychiat 44 (1998) 88-97
10. Benes F.M., McSparren J., Bird E.D., SanGiovanni J.P., and Vincent S.L. Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch Gen Psychiat 48 (1991) 996-1001
11. Beninger R.J., Cooper T.A., and Mazurski E.J. Automating the measurement of locomotor activity. Neurobeh Toxicol Ter 7 (1985) 79-85
12. Bennett B., Reynolds J., Prusky G., Douglas R., Sutherland R., and Thatcher G. Cognitive deficits in rats after forebrain cholinergic depletion are reversed by a novel NO mimetic nitrate ester. Neuropsychopharmacol 32 (2007) 505-513
13. Bernstein H.G., Bogerts B., and Keilhoff G. The many faces of nitric oxide in schizophrenia: a review. Schizophr Res 78 (2005) 69-86
14. Bernstein H.G., Stanarius A., Baumann B., Henning H., Krell D., Danos P., et al. Nitric oxide synthase-containing neurons in the human hypothalamus: reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics. Neuroscience 83 (1998) 867-875
15. Bon C.L.M., and Garthwaite J. Exogenous nitric oxide causes potentiation of hippocampal synaptic transmission during low-frequency stimulation via the endogenous nitric oxide-cGMP pathway. Eur J Neurosci 14 (2001) 585-594
16. Brorson J., Schumacker P., and Zhang H. Nitric oxide acutely inhibits neuronal energy production. J Neurosci 19 (1999) 147-158
17. Bujas-Bobanovic M., Bird D.C., Robertson H.A., and Dursun S.M. Blockade of phencyclidine-induced effects by a nitric oxide donor. Brit J Pharmacol 130 (2000) 1005-1012
18. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., and Carlsson M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 11 (2001) 237-260
19. Chadman K.K., Watson D.J., and Stanton M.E. NMDA receptor antagonism impairs reversal learning in developing rats. Behav Neurosci 120 (2006) 1071-1083
20. Cochran S.M., Kennedy M., McKerchar C.E., Steward L.J., Pratt J.A., and Morris B.J. Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacol 28 (2003) 265-275
21. Connell P.H. Amphetamine psychosis. Maudsley Monographs No. 5 (1958), Oxford University Press, London
22. Connop B.P., Boegman R.J., Beninger R.J., and Jhamandas K. Attenuation of malonate-induced degeneration of the nigrostriatal pathway by inhibition of nitric oxide synthase. Neuropharmacology 35 (1996) 459-465
23. Dall'Olio R., Gandolfi O., and Montanaro N. Effect of chronic treatment with dizocilpine (MK-801) on the behavioral response to dopamine receptor antagonists in the rat. Psychopharmacology 107 (1992) 591-594
24. Das I., Khan N., Puri B., Sooranna S., Belleroche J., and Hirsch S. Elevated platelet calcium mobilization and nitric oxide synthase activity may reflect abnormalities in schizophrenic brain. Biochem Bioph Res Co 212 (1995) 375-380
25. Geyer M.A., and Moghaddam B. Animal models relevant to schizophrenia disorders. In: Davis K.L., Charney D.S., Coyle J.T., and Nemeroff C. (Eds). Neuropsychopharmacology: The fifth generation of progress (2002), Lippincott Williams and Wilkins, Philadelphia 689-701
26. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry 153 (1996) 321-330
27. Green M.F., and Nuechterlein K.H. Should schizophrenia be treated as a neurocognitive disorder?. Schizophr Res 25 (1999) 309-318
28. Green M.F., Kern R.S., and Heaton R.K. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 72 (2004) 41-51
29. Hashimoto T., Volk D.W., Eggan S.M., Mirnics K., Pierri J.N., Sun Z., et al. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci 23 (2003) 6315-6326
30. Heaton R.K., Gladsjo J.A., Palmer B.W., Kuck J., Marcotte T.D., and Jeste D.V. Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry 58 (2001) 24-32
31. Hoffman D.C. The noncompetitive NMDA antagonist MK-801 fails to block amphetamine-induced place conditioning in rats. Pharmacol Biochem Be 47 (1994) 907-912
32. Idris N.F., Repeto P., Neill J.C., and Large C.H. Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and D-amphetamine in the rat. Psychopharmacology 179 (2005) 336-348
33. Insel T.R., and Scolnick E.M. Cure therapeutics and strategic prevention: raising the bar for mental health research. Mol Psychiatry 11 (2006) 11-17
34. Jentsch J.D., and Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacol 20 (1999) 201-225
35. Jentsch J.D., and Taylor J.R. Impaired inhibition of conditioned responses produced by subchronic administration of phencyclidine to rats. Neuropsychopharmacol 24 (2001) 66-74
36. Jentsch J.D., Taylor J.R., and Roth R.H. Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion. Neuropsychopharmacol 19 (1998) 105-113
37. Jentsch J., Tran A., Le D., Youngren K., Phil M., and Roth R. Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacol 17 (1997) 92-99
38. Jentsch D., Tran A., Taylor J., and Roth R. Prefrontal cortical involvement in phencyclidine-induced activation of the mesolimbic dopamine system: behavioral and neurochemical evidence. Psychopharmacology 138 (1998) 89-95
39. Jentsch J.D., Taylor J.R., Elsworth J.D., Redmond Jr. D.E., and Roth R.H. Altered frontal cortical dopaminergic transmission in monkeys after subchronic phencyclidine exposure: involvement in frontostriatal cognitive deficits. Neuroscience 90 (1999) 823-832
40. Karreman M., and Moghaddam B. The prefrontal cortex regulates the basal release of dopamine in the limbic striatum: an effect mediated by ventral tegmental area. J Neurochem 66 (1996) 589-598
41. Keilhoff G., Becker A., Grecksch G., Wolf G., and Bernstein H.G. Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cfos similar to those found in human schizophrenia. Neuroscience 126 (2004) 591-598
42. Kinney J.W., Davis C.N., Tabarean J., Conti B., Bartfai T., and Behrens M.M. A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons. J Neurosci 26 (2006) 1604-1615
43. Lewis D.A., and Gonzalez-Burgos G. Pathophysiologically based treatment interventions in schizophrenia. Nat Med 12 (2006) 1016-1022
44. Lewis D.A., Volk D.W., and Hashimoto T. Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology 174 (2004) 143-150
45. Lipton S., Choi Y., Pan Z., Sizheng L., Chen H., Sucher N., et al. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 364 (1993) 626-632
46. Lisman J.E., Coyle J.T., Green R.W., Javitt D.C., Benes F.M., Heckers S., et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 31 (2008) 234-242
47. Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., and Kelley R. Study of a new schizophrenomimetic drug; Sernyl. AMA Arch Neurol Psychiatry 81 (1959) 363-369
48. Mandillo S., Rinaldi A., Oliverio A., and Mele A. Repeated administration of phencyclidine, amphetamine and MK-801 selectively impairs spatial learning in mice: a possible model of psychotomimetic drug-induced cognitive deficits. Behav Pharmacol 14 (2003) 533-544
49. Marcotte E.R., Pearson D.M., and Srivastava L.K. Animal models of schizophrenia: a critical review. J Psychiat Neurosci 26 (2001) 395-410
50. Monfort P., Munoz M., Kosenko E., Llansola M., Sanchez-Perez A., Cauli O., et al. Sequential activation of soluble guanylate cyclase, protein kinase G and cGMP-degrading phosphodiesterase is necessary for proper induction of long-term potentiation in CA1 of hippocampus. Alterations in hyperammonemia. Neurochem Int 45 (2004) 895-901
51. Morris B.J., Cochran S.M., and Pratt J.A. PCP: from pharmacology to modeling schizophrenia. Curr Opin Pharmacol 5 (2005) 101-106
52. Muller U. Inhibition of nitric oxide synthase impairs a distinct form of long-term memory in the honeybee, Apis mellifera. Neuron 16 (1996) 541-549
53. A receptor α-1 subunit messenger RNA and human GABA transporter-1 (HGAT-1) messenger RNA expression. Neuroscience 93 (1999) 441-448
54. Palencia C.A., and Ragozzino M.E. The influence of NMDA receptors in the dorsomedial striatum on response reversal learning. Neurobiol Learn Mem 82 (2004) 81-89
55. Pitsikas N., Zisopoulou S., and Sakellaridis N. Nitric oxide donor molsidomine attenuates psychotomimetic effects of the NMDA receptor antagonist MK-801. J Neurosci Res 84 (2006) 299-305
56. Prast H., and Philippu H. Nitric oxide as a modulator of neuronal function. Prog Neurobio 64 (2001) 51-68
57. Reif A., Herterich S., Strobel A., Ehlis A.C., Jacob C.P., Wienker T., et al. A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal cortex function. Mol Psychiatry 11 (2006) 286-300
58. Reynolds G.P., and Beasley C.L. GABAergic neuronal subtypes in the human frontal cortex-development and deficits in schizophrenia. J Chem Neuroanat 22 (2001) 95-100
59. Reynolds G.P., Abdul-Monim Z., Neill J.C., and Zhang Z.J. Calcium binding protein markers of GABA deficits in schizophrenia - post mortem studies and animal models. Neurotoxicity Res 6 (2004) 57-61
60. Riley B., and Kendler K.S. Molecular genetic studies of schizophrenia. Eur J Human Genet 14 (2006) 669-680
61. Rund B.R. A review of longitudinal studies of cognitive functions in schizophrenia patients. Schizophr Bull 24 (1998) 425-435
62. Schwighofer N., and Ferriol G. Diffusion of nitric oxide can facilitate cerebellar learning: a simulation study. P Natl Acad Sci USA 97 (2000) 10661-10665
63. Smith S., Dringenberg H., Bennett B., Thatcher G., and Reynolds J. A novel nitrate ester reverses the cognitive impairment caused by scopolamine in the Morris water maze. Learn Memory 11 (2000) 3883-3886
64. Smolders I., De Klippel N., Sarre S., Ebinger G., and Michotte Y. Tonic GABA-ergic modulation of striatal dopamine release studied by in vivo microdialysis in the freely moving rat. Eur J Pharmacol 284 (1995) 83-91
65. 1A receptors. Behav Brain Res 191 (2008) 26-31
66. Thatcher G., Bennett B., Dringenberg H., and Reynolds J. Novel nitrates as NO mimetics directed at Alzheimer's disease. J Alzheimers Dis 6 (2004) S75-S84
67. Thatcher G., Bennett B., and Reynolds J. Nitric oxide mimetic molecules as therapeutic agents in Alzheimer's disease. Curr Alzheimer Res 2 (2005) 1-8
68. Thatcher G., Nicolescu A., Bennett B., and Toader V. Nitrates and NO release: contemporary aspects in biological and medicinal chemistry. Free Radical Bio Med 37 (2004) 1122-1143
69. Van der Meulen J.A.J., Bilbija L., Joosten R.N.J.M.A., de Bruin J.P.C., and Feenstra M.G.P. The NMDA-receptor antagonist MK-801 selectively disrupts reversal learning in rats. Neuroreport 14 (2003) 2225-2228
70. Vezina P., and Kim J.H. Metabotropic glutamate receptors and the generation of locomotor activity: interactions with midbrain dopamine. Neurosci Biobehav R 23 (1999) 577-589
71. Volk D.W., and Lewis D.A. Impaired prefrontal inhibition in schizophrenia: relevance for cognitive dysfunction. Physiol Behav 77 (2002) 501-505
72. West A.R., Galloway M.P., and Grace A.A. Regulation of striatal dopamine neurotransmission by nitric oxide: effector pathways and signaling mechanisms. Synapse 44 (2002) 227-245
73. Wilby M.J., and Hutchinson P.J. The pharmacology of chlormethiazole: a potential neuroprotective agent?. CNS Drug Rev 10 (2004) 281-294
74. Wolf M.E., Xue C., White F.J., and Dahlin S.L. MK-801 does not prevent acute stimulatory effects of amphetamine or cocaine on locomotor activity or extracellular dopamine levels in rat nucleus accumbens. Brain Res 666 (1994) 223-231
75. Xing G., Chavko M., Zhang L.X., Yang S., and Post R.M. Decreased calcium-dependent constitutive nitric oxide synthase (cNOS) activity in prefrontal cortex in schizophrenia and depression. Schizophr Res 78 (2002) 69-86
76. Yamada K., Noda Y., Hasegawa T., Komori Y., Nikai T., Sugihara H., et al. The role of nitric oxide in dizocilpine-induced impairment of spontaneous alternation behavior in mice. J Pharmacol Exp Ther 276 (1996) 460-466
77. Yao J., Leonard S., and Reddy R. Increased nitric oxide radicals in postmortem brain from patients with schizophrenia. Schizophrenia Bull 30 (2004) 923-934
78. Young D., and Scoville W.B. Paranoid psychosis in narcolepsy and the possible danger of Benzedrine treatment. Med Clin N Am 22 (1938) 637-646
79. Zhuo M., Hu Y., Schultz C., Kandel E., and Hawkins R. Role of guanylyl cyclase and cGMP-dependent protein kinase in long-term potentiation. Nature 368 (1994) 635-639
80. Zoroglu S., Herken H., Yurekli M., Uz E., Tutkun H., Savas H.A., et al. The possible pathophysiological role of plasma nitric oxide and adrenomedullin in schizophrenia. J Psychiat Res 36 (2002) 309-315